FDA Approves First Biosimilar Insulin Product
Semglee (insulin glargine-yfgn) is biosimilar to and interchangeable with Lantus (insulin glargine), provides cost-effective option
Diabetes
Free Fatty Acids Associated With Rapid Decline in Glomerular Filtration Rates in Type 1 Diabetes
Researchers identified lipidomic predictors of rapid decline of kidney function in individuals with type 1 diabetes.
Antidepressant Use May Aid Outcomes in Depression and Diabetes
Regular versus poor antidepressant use tied to lower risk for advanced diabetic complications, mortality in patients with depression and diabetes
Cycling Linked to Reduced All-Cause, CVD Mortality in Diabetes
Multivariable-adjusted hazard ratios for all-cause mortality reduced for 1 to 59, 60 to 149, 150 to 299, and ≥300 minutes/week
Glycemic Control Has Not Been Impacted by Pandemic
Despite drop in diabetes-related outpatient visits and testing, no negative association found with glycemic control
Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
High iPTH Linked With Cardiovascular Outcomes in Diabetic Kidney Disease
Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.
Glucose-Lowering Therapy Delayed for Newly Diagnosed T2DM Patients
Factors in therapeutic inertia examined in adults newly diagnosed with T2DM receiving primary care in the U.K.
Patiromer Prolongs Spironolactone Use Regardless of Diabetes Status
Patient with and without diabetes who received patiromer were more likely to remain on spironolactone at 12 weeks compared with those who received placebo, a subgroup analysis of the AMBER trial showed.
Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease
The approval was based on data from the phase 3 FIDELIO-DKD trial.
- Loading...
Loading...
Next post in Chronic Kidney Disease (CKD)
Loading... 
Loading...